As gene-modified cell therapy programs move into later-stage development, maintaining continuity across plasmid design and ...
Platform has the capability to reduce time from process development to GMP by 55 percent and deliver a drug product in fewer than 8 months nAAVigation platform will be launched at the Cell & Gene ...
6d
Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist
Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results